Key result
FKBP12 deficiency and low doses of rapamycin or SLF increased protein synthesis, enhanced refilling of sarcoplasmic reticulum Ca2+ stores, and improved skeletal muscle endurance in mice.
Low-dose rapamycin and SLF improve skeletal muscle function and fatigue resistance by modulating FKBP12 and increasing protein synthesis, without adverse cardiac effects.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for low-dose rapamycin in muscle disorders; human trials needed before clinical consideration.
Rapamycin at high doses (2-10 mg/kg body weight) inhibits mammalian target of rapamycin complex 1 (mTORC1) and protein synthesis in mice. In contrast, low doses of rapamycin (10 μg/kg) increase mTORC1 activity and protein synthesis in skeletal muscle. Similar changes are found with SLF (synthetic ligand for FKBP12, which does not inhibit mTORC1) and in mice with a skeletal muscle-specific FKBP12 deficiency. These interventions also increase Ca(2+) influx to enhance refilling of sarcoplasmic reticulum Ca(2+) stores, slow muscle fatigue, and increase running endurance without negatively impacting cardiac function. FKBP12 deficiency or longer treatments with low dose rapamycin or SLF increase the percentage of type I fibers, further adding to fatigue resistance. We demonstrate that FKBP12 and its ligands impact multiple aspects of muscle function.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2014) studied Skeletal muscle fatigue. Low dose rapamycin, SLF, or FKBP12 deficiency vs. Saline or CRE+ (wild-type) mice was evaluated on Skeletal muscle fatigue, protein synthesis, and Ca2+ influx. FKBP12 deficiency and low doses of rapamycin or SLF increased protein synthesis, enhanced refilling of sarcoplasmic reticulum Ca2+ stores, and improved skeletal muscle endurance in mice.
Synapse has enriched 10 related papers. Consider them for comparative context: